impedimed[®]

ImpediMed Limited 1/50 Parker Court, Pinkenba, QLD, 4008 Australia

E: investorrelations@impedimed.com

W: impedimed.com

14 April 2025

Companies Announcements Office Australian Securities Exchange

Change of registry address notification

In accordance with ASX Listing Rule 3.15.1, ImpediMed Limited (ASX: IPD) (**ImpediMed**) advises that with effect from today, 14 April 2025, the Sydney office of ImpediMed's share registry, MUFG Corporate Markets (AU) Limited (**MUFG**), has moved to:

MUFG Corporate Markets (AU) Limited Liberty Place Level 41 161 Castlereagh Street Sydney NSW 2000

MUFG telephone numbers and postal address remain unchanged.

Approved for release by the Company Secretary of ImpediMed Limited.

For more information, contact Dr Parmiot Bains or McGregor Grant on +61 7 3860 3700.

About ImpediMed

Founded in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.